Loading
Ruth Plummer is an early-phase trialist who ran the first-in-human study of a PARP inhibitor.
Ruth Plummer is Professor of Experimental Cancer Medicine at Newcastle and Clinical Advisor to Cancer Research UK. Her specialisms are early-phase trials, DNA repair inhibitors and experimental cancer medicine. She led the first clinical trial of a PARP inhibitor, rucaparib, in 2005, and her Clinical Cancer Research paper reported the phase I study of the PARP inhibitor AG014699 combined with temozolomide in patients with advanced solid tumours. She directs experimental cancer medicine in Newcastle within the Cancer Research UK network. Her publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors | Clinical Cancer Research | 2008 |